The latest update is out from Adverum Biotechnologies (ADVM).
Adverum Biotechnologies, Inc. is undergoing a shift in its leadership team, with the appointment of Rabia Gurses Ozden, M.D. as Chief Medical Officer, a change effective June 10, 2024. Dr. Ozden’s new role prompts her resignation from the Board and its Research and Development Committee. Concurrently, Szilárd Kiss, M.D. has been appointed to the Board to fill the vacancy and is slated to serve until the 2026 Annual Meeting of Stockholders, bringing his extensive experience in ophthalmology and genetic medicine to the team. Dr. Kiss’s involvement with various biopharmaceutical companies and his academic tenure at Weill Cornell Medical College, combined with his equity stake in the company, position him as a valuable addition to the Board.
See more data about ADVM stock on TipRanks’ Stock Analysis page.
